Sudarshan Pharma Industries Ltd · BSE:SUDARSHAN
Sudarshan Pharma Industries — Investor Presentation (August 2025)
63 slides from Sudarshan Pharma Industries's investor presentation, August 2025
Slide 1: Sudarshan Pharma Industries Limited Investor Presentation
Sudarshan Pharma Industries Limited INVESTOR PRESENTATION Investor Presentation
Slide 2: Company Background & Overview
Company Background & Overview
Slide 3: A Specialty Chemicals & Pharmaceutical Manufacturing Company
A Specialty Chemicals & Pharmaceutical Manufacturing Company 18 Years Founded in 2008, Sudarshan Pharma Industries Limited (SPIL) is engaged in manufacturing and sourcing of Chemicals and Pharmaceutical products Diversified Products The Company specializes in host of products from rock chemicals int
Slide 4: Milestones
Milestones 2008- 2011- 2013- 2015- 2017- 2019- 2021- 2023- 2010 2012 2014 2016 2018 2020 2022 2024 • 2008 - Expanded • Generic • Established our • Over 5,000 medical • Manufacturing of • Launch Hart Kit • IVD-Section Got • Developing new market reach by formulations for footprints in practitioners N
Slide 5: Subsidiaries
Subsidiaries SUDARSHAN PHARMA INDUSTRIES LTD. Wholly Owned Subsidiaries 51% Ownership Ratna Lifescience Private Limited Life Science Chemical Private Limited Ishwari Healthcare Private Limited Existing Products: Existing Products: Existing Products: • Tannin extracts • Polyglycolic Acid Sutures • Ge
Slide 6: Subsidiaries
Subsidiaries SUDARSHAN PHARMA INDUSTRIES LTD. Wolly-owned Subsidiaries 70% Ownership Sudarshan Pharma Industries Sudarshan Pharma Lifescience Cibachem General Sudarshan Maven Pharma Private Private Limited, Singapore Private Limited Trading LLC, Dubai Limited The Company is engaged in Existing Produ
Slide 7: Ratna Lifescience: Turnaround story
Ratna Lifescience : Turnaround story Revenue from Operations (Rs Mn) Profit After Tax (Rs Mn) 92.2 Over the past three years, the company was 7.1 operating at a loss. Since the takeover by Sudarshan Pharma Industries Ltd., we have 21.5 successfully turned it around into a profitable 5.0 0.2 -2.4 org
Slide 8: Ishwari Healthcare Pvt Ltd.
Subsidiaries SUDARSHAN PHARMA INDUSTRIES LTD. Ishwari Healthcare Pvt Ltd. A 51% subsidiary of Sudarshan Pharma Industries Ltd Ishwari Healthcare Private Limited was incorporated on 31st January 2011 and is dedicated to serve world market by providing superior services, user‐friendly and state‐of‐the
Slide 9: Sudarshan Pharma Industries Limited: Palghar plant
Sudarshan Pharma Industries Limited : Palghar plant • The company has established Unit 2 in Palghar, Maharashtra • The facility's core operations cover a broad spectrum of activities, including raw material testing, formulation dispensing, batch manufacturing in line with approved standards, as well
Slide 10: Existing Business Layout
Existing Business Layout Business Layout The company is focusing on increasing manufacturing capabilities and has started Vertical Integration for expansion in the following segments: Branded Generics Finished Formulation and F&O Research & API Manufacturing Development and Import Intermediates for
Slide 11: New Acquisitions & Partnerships
New Acquisitions & Partnerships Ardes Laboratories Pvt Ltd • In November 2024, Sudarshan Pharma Industries Ltd. and Ardes Laboratories Pvt. Ltd., Hyderabad, Telangana, entered into a Memorandum of Understanding (MoU) aimed at leveraging their combined strengths to enhance business growth, increase t
Slide 12: Organic Growth
Organic Growth Daundi Biological Pvt Ltd • The Company has formalized a Rent Agreement with M/s. Daundi Biological Private Limited for the lease of premises to establish a new Research & Development (R&D) formulation centre. The agreement is for a period of five years, commencing on 29th December 20
Slide 13: Export Opportunity
Export Opportunity In FY 25-26: We are Targeting Majorly to our Own Manufacturing API Products Including (Oncology) and Finish Formulation (Keeping Products Registration on priority) and Targeting Non Regulated Market for which we have made the Loan Licenses with many manufacturers to be cost effect
Slide 14: Key Products
Key Products SPECIALITY GREEN CHEMICALS Acetonitrile Tetrahydrofuran (THF) 1,4-Dioxane DMF/DMSO NMP (N-Methyl-2- Meta xylene N-Heptane Diethanolamine pyrrolidone) PHARMA DIVISION Out of 96 products, 56 are registered under the “R” Trade Mark. • SPIL has introduced a novel drug delivery system under
Slide 15: Our Esteemed Clientele
Our Esteemed Clientele Sudarshan Pharma Industries Limited | Investor Presentation
Slide 16: Operating in over 10 countries globally
Operating in over 10 countries globally Exporting Countries Jordan Lebanon Nepal Qatar Saudia UAE Arabia Mali Bangladesh Oman Nigeria Sri Lanka Uganda Ghana Somalia Congo Kenya South Africa PAN India presence Sudarshan Pharma Industries Limited | Investor Presentation
Slide 17: Lead Management
Lead Management Mr. Hemal V. Mehta |Chairman & Managing Director Hemal Mehta, Founder-Promoter and Chairman & Managing Director of Sudarshan Pharma Industries Ltd., brings 26 years of extensive experience in the pharmaceutical and chemical manufacturing industry. He is recognized for his expertise i
Slide 18: Board of Directors
Board of Directors Umesh Luthra| Independent Director Jaya Singhania| Independent Director Registered as an Independent Director with the databank Result oriented Biotech Professional with General of IICA. She has authored numerous write-ups on Management knowledge having about 29+ years of corporat
Slide 19: Key Personnel
Key Personnel Senior Key Personnel Existing Key Personnel Dr. Vishwas Joshi Mr. Nirav Shah Mr. Amit Mehta Mrs. Namrata Mehta Company Secretary Purchase Manager Vice president Sales Mr. Shailesh Bathiya Mr. Shrinivas Patil Mr. Milan shah Mrs. Shrishti Mayekar Export Head Purchase Manager Sales Head D
Slide 20: H2 & FY25 Financial Metrics: Focus on Margin Optimization and Profit Growth
H2 & FY25 Financial Metrics: Focus on Margin Optimization and Profit Growth Revenue from Operations Operating EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) INR in Crs 7.3% 6.2% 8.4% 4.9% 7.9% 2.6% 2.8% 3.2% 2.5% 3.6% +9.0% +75.0% +39.3% 505.0 463.5 39.9 16.0 +62.0% +51.9% +19.6% 11.5 23.4 10.0 277
Slide 21: H2 & FY25 Consolidated Profit & Loss Statement
H2 & FY25 Consolidated Profit & Loss Statement Particulars (Rs.Crs) H2FY25 H2FY24 Y-o-Y H1FY25 H-o-H FY25 FY24 Y-o-Y Revenue from Operations 277.3 231.7 19.6% 227.8 21.7% 505.0 463.5 9.0% Cost of Material Consumed/Other Direct Costs 5.3 3.2 3.7 8.9 6.3 Purchases of Stock-in trade 273.2 209.8 211.9 4
Slide 22: Consolidated Balance Sheet
Consolidated Balance Sheet EQUITY & LIABILITIES (INR. Crs) Mar-25 Mar-24 ASSETS (Rs. Crs) Mar-25 Mar-24 Equity Share Capital 24.1 24.1 Property, Plant and Equipment 20.0 20.5 Reserves & Surplus 103.6 87.6 Capital work‐in‐progress 6.0 1.9 Money Received Towards Warrant 3.8 0.0 Intangible assets 0.3 0
Slide 23: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (INR in Cr) Mar-25 Mar-24 Profit before Tax 21.6 15.2 Adjustment for Non-Operating Items 20.0 9.4 Operating Profit before Working Capital Changes 41.6 24.6 Changes in Working Capital -3.5 -16.5 Cash Generated from Operations 38.2 8.2 Less: Direct Taxes pa
Slide 24: Working Capital Break-up
Working Capital Break-up Working Capital Management (in Days) Net Working Capital (in Days) 28 63 64 54 116 101 96 75 75 73 68 66 64 59 48 45 Mar-22 Mar-23 Mar-24 Mar-25 Inventory Debtors Creditors Sudarshan Pharma Industries Limited | Investor Presentation
Slide 25: Potential Opportunity
Potential Opportunity 1) Hyderabad Unit 2) Gujrat Unit 1 3) Africa Unit 4) USFDA Unit 5) Gujrat Unit 2
Slide 26: Hyderabad Unit
Hyderabad Unit Hyderabad Unit 1 Hyderabad, India, Hyderabad Unit is bulk drug & intermediate manufacturing company. It has been developed about 50 potential API Key starting materials of having an outstanding commercial technology. Few key starting materials were Holded Patent rights and those inter
Slide 27: Manufacturing Facility Hyderabad Unit
MANUFACTURING FACILTY HYDERABAD UNIT R&D Center Factory Site Synthetic R&D HPLC AR&D QC wet lab
Slide 28: USFDA Plant
Opportunity to acquire USFDA unit in India USFDA Plant • Proposed Unit India established in 1999 • Three manufacturing blocks (A, B and C) • Warehouse facilities for Raw materials, Intermediates, APIs and Engineering consumable items • Independent Quality Assurance and Quality Control functions • Su
Slide 29: Key Features of Facility
Key features of Facility Manufacturing blocks • Total Reactor capacity – 164 KL • Filters - Centrifuge, Nutsch Filter, Sparkler Filter etc. • Dryers – Tray dryer, Vacuum Tray Dryer, Nauta Dryer, Agitated Nutsch Filter Dryer • Multi mill, Sifter, Pin mill and Air Jet mill • Blender • Powder processin
Slide 30: Financials
FINANCIALS Particulars FY 22-23 FY 23-24 FY 24-25 FY 25-26 Total Revenue 385 246 500 600 Material Cost 280 160 325 375 Gross Margin 105 86 175 220 Plant Expenses Personnel cost 21 21 25 28 Contract labor cost 3 3 5 6 Power, fuel & Water expenses 22 16 30 40 Repair & maintenance cost 4 7 10 12 Consum
Slide 31: Gujarat Unit
Gujrat unit 2 Gujarat Unit 2 They are focused on developing and manufacturing Active Pharmaceutical Ingredients (APIs) and registered Pharma Intermediates for human health to the domestic as well as international markets. As an active pharmaceutical ingredients (API) manufacturing company, they deve
Slide 32: Gujarat Unit
Gujrat unit 2 Gujarat Unit 2 . Sudarshan Pharma Industries Limited | Investor Presentation
Slide 33: Industry Overview
Industry Overview
Slide 34: Pharma Industry: Key Catalysts for Growth
Pharma Industry : Key Catalysts for Growth Recognizing the potential for growth, the Government of India took up the initiative of developing the Indian Pharmaceuticals sector by creating a separate Department in July 2008. The Department is entrusted with the responsibility of policy, pIanning, dev
Slide 35: Industry Overview
Industry Overview Indian Pharmaceutical Market (US$ billion) • US$ 42 bn India's pharmaceutical market in 2021. It is likely to reach US$ 65 billion by 2024 and further expand to reach ~US$ 120-130 billion by 2030. 450 • 40% of generic demand in the US, and 25% of all medicine in the UK is supplied
Slide 36: India - a strong exporter of pharma & Specialty Chemicals Globally
INDIA- a strong exporter of pharma & Specialty Chemicals Globally A significant and rising player in the Global Pharmaceutical industry India’s drugs and pharmaceutical exports FDI inflows in the Indian drugs and Pharma sector stood at US$ 27.9 billion in FY24 reached US$236 Mn. between April 2023-J
Slide 37: Addressing the Opportunity
Addressing the Opportunity The central government has earmarked ~Rs { @ 100 billion for the bulk drug industry, including Rs 30 billion for the promotion of bulk drug 3 parks (for the next five years) and Rs 69.4 billion for a production-linked incentive scheme for the promotion of domestic manufact
Slide 38: Key Problem Area
Key Problem Area Dependence on China for Import of key APIs Categories Imports from China (%) Antibiotics 75-80 Hormones, Prostaglandins, Thromboxane & Leukotrienes 50-55 Pro-Vitamins & Vitamins 55-60 Other heterocyclic compounds 80-85 Other organic compounds 70-75 India imports ~70% of Intermediate
Slide 39: Key Developments in Sudarshan
Key Developments in Sudarshan
Slide 40: R&D for New Molecules & New Technology in association with Amity University
R&D for New Molecules & New Technology in association with Amity University SPIL has entered into a strategic partnership with Dr. William Selvamurthy at Amity University, a distinguished leader in global education who has established a benchmark for excellence by aligning educational practices, the
Slide 41: Investments under the Government PLI Program
Investments under the Government PLI Program The company has received approval under the Production Linked Incentive (PLI) scheme to promote the domestic manufacturing of critical Key Starting Materials (KSM), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs) in India. Unit 1: V
Slide 42: Sudarshan Group's Pharma Project Gains 40% PSI-2019 Subsidy
Sudarshan Group's Pharma Project Gains 40% PSI-2019 Subsidy Maharashtra Govt. Subsidies for new project • Pharma Items Manufacturing Project by Sudarshan Group at Mahad MIDC (C Zone) has following subsidy benefits from State Government of Maharashtra, Industries Department, Under PSI-2019 scheme. •
Slide 43: New Products & Markets
New Products & Markets Some of Our New Products : New Clientele: Chemical Sector: Pharma Sector: Oncology API’s: • 1, 4-Dioxane • Fluconazole, • Gemcitabine • 2 Methyl THF • Levocetrizine Dihydrochloride, • T9 • Acetonitrile • Chlorozoxazone, • Apalutamide • IODINE • Pregabalin, • Olaparib • Pyridin
Slide 44: Future Outlook
Future Outlook Strategic Expansion into New Products & Markets Establishing a State-of-the-Art Launching of Focusing on Product Expanding Pharma Sales Manufacturing Facility Advanced Healthcare Innovation and Market Domestically and Globally The company is focusing on increasing Solutions Penetratio
Slide 45: Financial Performance
FINANCIAL PERFORMANCE
Slide 46: Performance in Charts
Performance in Charts Revenue from Operations (Rs Cr) EBITDA (Rs Cr) PAT (Rs Cr) 3.1% 3.2% 4.9% 7.9% 1.5% 1.5% 2.5% 3.2% +12% 463.5 505.0 39.9 +45% 16.0 461.3 +54% 357.1 11.5 22.8 14.7 7.0 10.9 5.2 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 R0CE (%) ROE (%) Debt to Equity (x) 39.9 2
Slide 47: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Particulars (Rs.Crs) FY24 FY23 FY22 FY21 Revenue from Operations 463.5 461.3 357.1 193.4 Cost of Material Consumed/Other Direct Costs 6.3 0.3 0.0 1.7 Purchases of Stock-in trade 424.0 457.2 358.0 184.2 Change in Inventories of Finished goods & Work in
Slide 48: Consolidated Balance Sheet
Consolidated Balance Sheet EQUITY & LIABILITIES (INR. Crs) Mar-24 Mar-23 Mar-22 Mar-21 ASSETS (Rs. Crs) Mar-24 Mar-23 Mar-22 Mar-21 Equity Share Capital 24.1 24.1 9.7 9.5 Property, Plant and Equipment 20.5 19.0 6.3 6.0 Reserves & Surplus 87.6 76.9 20.0 13.0 Capital work‐in‐progress 1.9 0.0 0.5 0.0 N
Slide 49: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (INR in Cr) Mar-24 Mar-23 Mar-22 Mar-21 Profit before Tax 15.2 9.5 7.1 3.6 Adjustment for Non-Operating Items 9.4 5.8 4.0 3.9 Operating Profit before Working Capital Changes 24.6 15.3 11.2 7.4 Changes in Working Capital -16.5 -42.0 -13.2 -3.7 Cash Generat
Slide 50: SPIL Consolidated (After Expansion): Business Plan FY2025-30
SPIL CONSOLIDATED (AFTER EXPANSION): BUSINESS PLAN FY2025-30 Fig. in Rs. Crs Acquisition_Capex FY23-24A FY24-25A FY25-26F FY26-27F FY27-28F FY28-29F FY29-30F Acquisitions-Assets - - 243.95 - - - - Growth Funds-Capex 14.50 4.67 38.65 42.08 29.73 19.91 9.47 Growth Funds-LT Working Capital Margin - - 1
Slide 51: SPIL Consolidated (After Expansion): Business Plan FY2025-30
SPIL CONSOLIDATED (AFTER EXPANSION): BUSINESS PLAN FY2025-30 Fig. in Rs. Crs DSO_306 80.4 96.6 90.0 90.0 90.0 90.0 90.0 Creditors 56.71 91.83 126.50 170.15 202.86 227.58 244.73 DCOGS_330 42.5 65.2 55.0 55.0 55.0 55.0 55.0 Net Working Capital 151.57 208.81 292.62 405.52 492.14 558.83 604.80 DSO_365 1
Slide 52: SPIL Consolidated (After Expansion): Business Plan FY2025-30
SPIL CONSOLIDATED (AFTER EXPANSION): BUSINESS PLAN FY2025-30 Fig. in Rs. Crs Balance Sheet-Liabilities FY23-24A FY24-25A FY25-26F FY26-27F FY27-28F FY28-29F FY29-30F Capital & Reserves 111.71 131.41 508.75 616.57 767.87 954.96 1,166.51 Capital_HO Contribution 24.07 24.07 24.97 24.97 24.97 28.69 28.6
Slide 53: SPIL Consolidated (After Expansion): Business Plan FY2025-30
SPIL CONSOLIDATED (AFTER EXPANSION): BUSINESS PLAN FY2025-30 Fig. in Rs. Crs Change in Other Current Liabilities -5.47 4.64 4.47 3.18 2.15 1.06 CF from Operations (A) -49.26 1.69 16.26 86.95 142.94 187.58 CF from Investing Activities: Acquisitions-Assets - - - - - - Growth Funds-Capex -4.67 -282.60
Slide 54: SPIL Consolidated (After Expansion): Business Plan FY2025-30
SPIL CONSOLIDATED (AFTER EXPANSION): BUSINESS PLAN FY2025-30 Fig. in Rs. Crs Key Ratio's CAGR (5YR) FY23-24A FY24-25A FY25-26F FY26-27F FY27-28F FY28-29F FY29-30F (FY25-30) Earning Per Share (EPS) 62.1% 0.5 0.7 2.7 4.3 6.1 6.5 7.4 Book Value Per Share (BVPS) 50.3% 4.6 5.3 8.5 12.8 18.8 33.3 40.7 Cas
Slide 55: SPIL Consolidated (Existing Business): Business Plan FY2025-30
SPIL CONSOLIDATED (EXISTING BUSINESS): BUSINESS PLAN FY2025-30 Fig. in Rs. Crs Acquisition_Capex Basis FY23-24A FY24-25A FY25-26F FY26-27F FY27-28F FY28-29F FY29-30F Acquisitions-Assets - - - - Growth Funds-Capex 15.00 14.50 4.67 6.77 6.09 7.00 8.06 9.26 Growth Funds-LT Working Capital Margin - - -
Slide 56: SPIL Consolidated (Existing Business): Business Plan FY2025-30
SPIL CONSOLIDATED (EXISTING BUSINESS): BUSINESS PLAN FY2025-30 Fig. in Rs. Crs DSO_306 80.4 96.6 90.0 90.0 90.0 90.0 90.0 Creditors 55 56.71 91.83 92.07 104.83 119.35 135.86 154.65 DCOGS_330 42.5 65.2 55.0 55.0 55.0 55.0 55.0 Net Working Capital 151.57 208.81 204.25 234.60 269.46 309.51 355.49 DSO_3
Slide 57: SPIL Consolidated (Existing Business): Business Plan FY2025-30
SPIL CONSOLIDATED (EXISTING BUSINESS): BUSINESS PLAN FY2025-30 Fig. in Rs. Crs Balance Sheet-Liabilities Basis FY23-24A FY24-25A FY25-26F FY26-27F FY27-28F FY28-29F FY29-30F Capital & Reserves 111.71 131.41 472.78 510.80 559.76 622.08 700.68 Capital_HO Contribution 24.07 24.07 24.97 24.97 24.97 28.6
Slide 58: SPIL Consolidated (Existing Business): Business Plan FY2025-30
SPIL CONSOLIDATED (EXISTING BUSINESS): BUSINESS PLAN FY2025-30 Fig. in Rs. Crs Change in Other Current Assets -4.86 3.20 -4.57 -5.26 -6.04 -6.94 Change in Sundry Creditors 35.12 0.24 12.76 14.52 16.51 18.79 Change in Other Current Liabilities -5.47 0.62 0.68 0.79 0.91 1.04 CF from Operations (A) -49
Slide 59: SPIL Consolidated (Existing Business): Business Plan FY2025-30
SPIL CONSOLIDATED (EXISTING BUSINESS): BUSINESS PLAN FY2025-30 Fig. in Rs. Crs Assumptions Basis FY23-24A FY24-25A FY25-26F FY26-27F FY27-28F FY28-29F FY29-30F Revenue Rs. Crs Sale Price Per MT API, Intermediate & Active 466.15 507.57 609.08 700.44 805.51 926.34 1,065.29 Pharmaceutical Ingredients T
Slide 60: SPIL Consolidated (Existing Business): Business Plan FY2025-30
SPIL CONSOLIDATED (EXISTING BUSINESS): BUSINESS PLAN FY2025-30 Fig. in Rs. Crs RM & Consumables Days 3 3 20 20 20 20 20 Stock in Process Days - - 10 10 10 10 10 FG Days 61 96 40 40 40 40 40 Receivable Collection Terms Days 80 97 90 90 90 90 90 Creditors Payment Terms Days 42.5 65.2 55 55 55 55 55 Ot
Slide 61: Participated in the GlobeChemShow International Exhibition 2024
Participated in the GlobeChemShow – International Exhibition 2024 In 2025, the chemical and pharmaceutical industries are projected to prioritize innovation, sustainability, and resilience as key drivers of efficiency and growth Sudarshan Pharma Industries Limited | Investor Presentation
Slide 62: Strategic Acquisition Plans for 2025-2026
STATEGIC ACQUISTION PLANS FOR 2025 – 2026 PART A : Strategic Acquisition Manufacturing unit In India PART B : Strategic Acquisition in Africa for Manufacturing & Sales PART C : International Europe & Gulf Acquisition PART A : Planned Strategic Acquisition Manufacturing unit In India 1.Hyderabad Unit
Slide 63: Sudarshan Pharma Industries Limited (SPIL) Vision: 2020 to 2035
Sudarshan Pharma Industries Limited (SPIL) Vision: 2020 to 2035 Sudarshan Pharma Industries Limited | Investor Presentation
Sudarshan Pharma Industries — Investor Presentation (August 2025) on 6ix